Last updated: February 15, 2026
What is NDC 70710-1069?
The National Drug Code (NDC) 70710-1069 corresponds to a specific pharmaceutical product. Based on current publicly available data, this NDC is associated with Xyrem (sodium oxybate), a Schedule III drug used to treat narcolepsy with cataplexy. It is produced by Jazz Pharmaceuticals.
Market Context
Market Size & Demand
Sodium oxybate's market hinges on narcolepsy prevalence, estimated at roughly 1 in 2,000 to 1 in 3,000 people in the U.S. (per NIH). The incidence is stable, but diagnosis rates impact overall demand.
Key Market Factors
- Prevalence of Narcolepsy: Estimated at approximately 135,000 patients in the U.S.
- Approved Indications: Narcolepsy (with and without cataplexy), off-label uses are minimal.
- Competitive Landscape: Other treatments include modafinil, armodafinil, and pitolisant. Sodium oxybate remains the most effective for cataplexy.
- Payment & Reimbursement: Covered via insurance with high co-pays, influencing patient access.
Regulatory & Market Dynamics
- The drug's Schedule III status limits prescribing flexibility versus Schedule IV meds.
- The expanding recognition of narcolepsy and sleep disorders increases intervention awareness.
- Jazz Pharmaceuticals maintains exclusivity through patents and REMS regulations, constraining generic entry.
Price Analysis
Current Price Benchmarks
- Wholesale Acquisition Cost (WAC): Approximately $63.30 per 1 mL vial (as of 2023; varies by distributor).
- Average Weekly Cost: For a standard dose (e.g., 9 g nightly), the weekly retail cost exceeds $8,000.
- Insurance Impact: Patients typically face co-pays of $50–$150 per month; insurer reimbursements drive the upper boundary of real-world prices.
Pricing Compared to Competitors
- Sodium oxybate (Xyrem): Historically high, driven by patent protection and limited competition.
- Off-brand or alternative meds: Significantly lower, but with reduced efficacy, particularly for cataplexy.
Price Projection Insights
Short-term (1–2 years)
- Stable Pricing: No imminent generic filings due to REMS restrictions and patent protections.
- Reimbursement patterns: Likely to remain stable, subject to insurance coverage shifts.
Medium-term (3–5 years)
- Patent Expiry & Biosimilar Entry: Expected patent expiration around 2028, potentially allowing biosimilar or generic versions.
- Potential Price Decline: Introduction of biosimilars or generics could reduce prices by 30–50%, depending on market penetration.
- Market Expansion: Greater disease awareness and off-label uses may sustain or slightly increase demand, offsetting price reductions.
Long-term (5+ years)
- Market Consolidation & Competition: The emergence of generics will strongly influence pricing, possibly leading to a 50%+ decrease.
- Regulatory & Reimbursement Shifts: Changes in regulatory policies may further moderate prices.
Risks & Opportunities
- Patent Litigation: Prolonged patent litigation could delay generics, maintaining high prices.
- Market Penetration: Increased off-label use or new formulations could extend the current price levels.
- Regulatory Changes: Modifications to REMS or scheduling could impact supply, demand, and pricing.
Key Takeaways
- NDC 70710-1069 corresponds to Xyrem (sodium oxybate), with a high current retail cost driven by patent exclusivity.
- The market is constrained by low prevalence, high regulatory barriers, and limited competition.
- Prices are expected to hold steady short-term, with significant declines possible after patent expiry (anticipated around 2028) due to biosimilar entry.
- Reimbursement trends and evolving treatment guidelines will influence actual patient access and prices.
- Long-term pricing reductions could range from 30–50%, depending on market dynamics.
FAQs
1. When does the patent for sodium oxybate (Xyrem) expire?
Patent protection is expected to expire around 2028, opening potential for biosimilar or generic competition.
2. What factors influence the drug’s price stability?
Regulatory protections, patent rights, limited competition, and high treatment effectiveness sustain current pricing.
3. Are there any approved biosimilars or generics?
No currently approved generics; biosimilar development may begin post-patent expiration.
4. How does insurance coverage affect actual patient costs?
Insurance generally covers most of the cost, with patient co-pays typically ranging from $50 to $150 monthly, depending on plan specifics.
5. What is the estimated revenue potential for the drug in the next five years?
Ahead of patent expiry, revenues remain stable; post-expiry, a potential 30–50% price decline combined with steady or increased demand could sustain substantial revenues.
References
- NIH: Narcolepsy Fact Sheet.
- Jazz Pharmaceuticals: Xyrem Pricing and Regulatory Data.
- SSR Health, 2023: Wholesale pricing trends.
- U.S. Food and Drug Administration (FDA): Drug patent expiry timelines.
- MarketWatch: Sleep disorder therapeutics market analysis, 2023.
